DRC to use a second Ebola vaccine by November
The Democratic Republic of Congo will introduce a second Ebola vaccine next month to counter the outbreak of the disease in the country.
List view / Grid view
The Democratic Republic of Congo will introduce a second Ebola vaccine next month to counter the outbreak of the disease in the country.
Health authorities in the Democratic Republic of Congo are planning to use a second vaccine to treat the Ebola virus.
A Biologics License Application and priority review has been approved by the FDA for an investigational Ebola vaccine.
The US HHS has committed to a contribution to help Merck manufacture its investigational V920 vaccine for the treatment of Ebola.
An Ebola clinical trial has been stopped early as Regeneron's REGN-EB3 therapy shows superiority to ZMapp in preventing Ebola deaths.
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
The health minister for the Democratic Republic of the Congo has stated an experimental Ebola vaccine will not be trialled in the country.
A recent report has presented an argument for updating vaccine development during health emergencies to increase efficiency.
The new hub is designed to speed the response to deadly pandemics by improving the development and manufacturing of vaccines – particularly in low- and middle-income countries...